Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 7/20 | 0.34 |
| ▸ | RAB9A | P51151 | 6/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 3/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24006607 | 0.80 | KDM4C (0.41) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL22275457 | 0.80 | KDM4C (0.41) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL22275507 | 0.80 | KDM4C (0.41) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL24006643 | 0.78 | KDM4C (0.40) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL6041327 | 0.78 | RAB9A (0.52) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL24015128 | 0.77 | KDM4C (0.42) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL7476046 | 0.77 | KMT2A (0.45) | NPC1RAB9AMEN1KMT2AICAM1 | |
| SCHEMBL15919565 | 0.77 | NAAA (0.40) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL25108415 | 0.76 | KDM4C (0.39) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL25108309 | 0.76 | KDM4C (0.39) | KDM4CL3MBTL1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2021226208-A2 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | KDM4C 1272/4885L3MBTL1 4110/4885NPC1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.